Cargando…
S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models
Cystic Fibrosis (CF) results from over 400 different disease-causing mutations in the CF Transmembrane Conductance Regulator (CFTR) gene. These CFTR mutations lead to numerous defects in CFTR protein function. A novel class of targeted therapies (CFTR modulators) have been developed that can restore...
Autores principales: | Allan, Katelin M., Astore, Miro A., Fawcett, Laura K., Wong, Sharon L., Chen, Po-Chia, Griffith, Renate, Jaffe, Adam, Kuyucak, Serdar, Waters, Shafagh A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709344/ https://www.ncbi.nlm.nih.gov/pubmed/36467478 http://dx.doi.org/10.3389/fped.2022.1062766 |
Ejemplares similares
-
Q1291H-CFTR molecular dynamics simulations and ex vivo theratyping in nasal epithelial models and clinical response to elexacaftor/tezacaftor/ivacaftor in a Q1291H/F508del patient
por: Allan, Katelin M., et al.
Publicado: (2023) -
Molecular dynamics and functional characterization of I37R-CFTR lasso mutation provide insights into channel gating activity
por: Wong, Sharon L., et al.
Publicado: (2021) -
Molecular Dynamics and Theratyping in Airway and Gut Organoids Reveal R352Q-CFTR Conductance Defect
por: Wong, Sharon L., et al.
Publicado: (2022) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023) -
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)